In this review, the authors discuss driving factors for the next generation of immunotherapy and target therapy, as well as how to increase the accuracy of the selection process for these therapies.
Browsing: personalized medicine
Could this new approach drive Parkinson’s disease into the age of personalized medicine?
In circadian rhythm sleep–wake disorders precision medicine is less developed than in other medical disciplines mainly because homeostatic sleep and circadian timing have a very complex phenotype with multiple genetic regulation mechanisms.
A group of researchers from the Dana-Farber Cancer Institute (MA, USA) has conducted the largest clinical study to date of genetic abnormalities in pediatric brain tumors.
Lauren Pulling highlights some of the key trending topics in neurology and neuroscience from 2016, as well as the top read articles of the year – take a look and let us know your thoughts.
A review providing examples of current omics that are applied in the field of pain including new diagnostics biomarkers, stratification of patients and new therapeutic targets.
A recent study has identified a potential genetic biomarker, SHOX2, for predicting the survival of patients with diffuse glioma brain tumors.
In this interview, Mark Frasier discusses a recent Editorial from the Michael J. Fox Foundation and looks ahead to the future of precision medicine for Parkinson’s disease.
In this Special Report, the authors discuss how the versatility of utilizing cancer-targeting alkylphosphocholine analogs may ultimately transform clinical management of primary and metastatic brain tumors.
In this perspective article, the author discusses potential holistic strategies to maintain QoL in people with PD and how they should consist of a multidisciplinary, personalized and patient-centered approach with timely administration of palliative care and efficient involvement of caregivers and family members.